Coronary flow impairment in asymptomatic patients with early stage type-2 diabetes
Detection by FFRCT

Mrgan, Monija; Nørgaard, Bjarne Linde; Dey, Damini; Gram, Jørgen; Olsen, Michael Hecht; Gram, Jeppe; Sand, Niels Peter Rønnow

Published in:
Diabetes & vascular disease research

DOI:
10.1177/1479164120958422

Publication date:
2020

Document version
Final published version

Document license
CC BY-NC

Citation for published version (APA):
Mrgan, M., Nørgaard, B. L., Dey, D., Gram, J., Olsen, M. H., Gram, J., & Sand, N. P. R. (2020). Coronary flow impairment in asymptomatic patients with early stage type-2 diabetes: Detection by FFRCT. Diabetes & vascular disease research, 17(5), 1-7. https://doi.org/10.1177/1479164120958422

Terms of use
This work is brought to you by the University of Southern Denmark through the SDU Research Portal. Unless otherwise specified it has been shared according to the terms for self-archiving. If no other license is stated, these terms apply:

- You may download this work for personal use only.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying this open access version.

If you believe that this document breaches copyright please contact us providing details and we will investigate your claim. Please direct all enquiries to puresupport@bib.sdu.dk

Download date: 23. Apr. 2021
Coronary flow impairment in asymptomatic patients with early stage type-2 diabetes: Detection by FFR\textsubscript{CT}

Monija Mrgan\textsuperscript{1}, Bjarne Linde Nørgaard\textsuperscript{2}, Damini Dey\textsuperscript{3}, Jørgen Gram\textsuperscript{4,5}, Michael Hecht Olsen\textsuperscript{6,7}, Jeppe Gram\textsuperscript{8} and Niels Peter Rønnow Sand\textsuperscript{1,9}

Abstract

**Purpose:** To determine the occurrence of physiological significant coronary artery disease (CAD) by coronary CT angiography (CTA) derived fractional flow reserve (FFR\textsubscript{CT}) in asymptomatic patients with a new diagnosis (<1 year) of type-2 diabetes mellitus (T2DM).

**Methods:** FFR\textsubscript{CT}-analysis was performed from standard acquired coronary CTA data sets. The per-patient minimum distal FFR\textsubscript{CT}-value (d-FFR\textsubscript{CT}) in coronary vessels (diameter $\geq 1.8$ mm) was registered. The threshold for categorizing FFR\textsubscript{CT}-analysis as abnormal was a d-FFR\textsubscript{CT} $\leq 0.75$. Total plaque volume and volumes of calcified plaque, non-calcified plaque, and low-density non-calcified plaque (LD-NCP) were assessed by quantitative plaque analysis.

**Results:** Overall, 76 patients; age, mean (SD): 56 (11) years; males, n (%): 49 (65), were studied. A total of 57% of patients had plaques. The d-FFR\textsubscript{CT} was $\leq 0.75$ in 12 (16%) patients. The d-FFR\textsubscript{CT}, median (IQR), was 0.84 (0.79–0.87). Median (range) d-FFR\textsubscript{CT} in patients with d-FFR\textsubscript{CT} $\leq 0.75$ was 0.70 (0.6–0.74). Patients with d-FFR\textsubscript{CT}$\leq 0.75$ versus d-FFR\textsubscript{CT} $> 0.75$ had numerically higher plaque volumes for all plaques components, although only significant for the LD-NCP component.

**Conclusion:** Every sixth asymptomatic patient with a new diagnosis of T2DM has hemodynamic significant CAD as evaluated by FFR\textsubscript{CT}. Flow impairment by FFR\textsubscript{CT} was associated with coronary plaque characteristics.

**Keywords**

Type-2 diabetes mellitus, coronary computed tomography angiography, coronary plaque analysis, coronary computed tomography angiography derived fractional flow reserve, FFR, AutoPlaque

Introduction

Coronary computed tomography angiography (CTA) is recommended as a first line non-invasive test in patients suspected of coronary artery disease (CAD).\textsuperscript{1,2} Beyond assessment of diameter stenosis, coronary CTA enables detailed analysis of the burden, and characteristics of coronary plaques.\textsuperscript{3} Specific plaque properties such as low-density and positive remodeling are associated with an unfavorable clinical outcome,\textsuperscript{4} and it has been demonstrated that adverse plaque features independently of stenosis severity are associated to impaired coronary flow.\textsuperscript{5–8}
Recently, coronary CTA derived fractional flow reserve (FFR\textsubscript{CT}) has emerged for non-invasive physiological evaluation of CAD\textsuperscript{6} before referral to invasive assessment in patients with stable angina pectoris. When validated against invasive FFR\textsuperscript{10-12} the reference standard for decision-making on coronary revascularization,\textsuperscript{1,13} FFR\textsubscript{CT} demonstrated high diagnostic performance. Moreover, FFR\textsubscript{CT} has revealed an enhanced diagnostic sensitivity compared to stress perfusion imaging by single photon emission computerized tomography\textsuperscript{14} and cardiac magnetic resonance.\textsuperscript{15} FFR\textsubscript{CT} testing may change the downstream management of patients,\textsuperscript{16,17} and recently, it was demonstrated that the numerical value of FFR\textsubscript{CT} is an independent predictor of outcomes.\textsuperscript{18-20}

The prevalence of CAD is high both at early\textsuperscript{21} and advanced phases of type-2 diabetes mellitus (T2DM).\textsuperscript{22} A strategy of identifying asymptomatic persons who may benefit from preventive medication has been debated for years.\textsuperscript{23} In one prospective randomized study however, screening with traditional coronary CTA failed to demonstrate any incremental prognostic gain in T2DM.\textsuperscript{24} To the best of our knowledge, no previous study has assessed the hemodynamic significance of CAD in patients with newly diagnosed T2DM.

Consequently, this exploratory study sought to determine the occurrence of physiological significant coronary stenosis by FFR\textsubscript{CT} and to relate these estimates with coronary plaque characteristics in asymptomatic patients with newly diagnosed T2DM.

Materials and methods

From March 2014 to August 2016, a total of 213 adult individuals diagnosed with T2DM (hemoglobinA1c >47 mmol/mol and plasma glucose >7 mmol/L) within the last year were identified via general practitioners or outpatient clinics in Region South of Denmark, and invited by letter to participate in this study. A detailed description of patient cohort exclusions criteria and demographic data have been published previously.\textsuperscript{21}

This post-hoc study was approved by the Regional Scientific Ethical Committee for Southern Denmark (S-20140137) and by the Danish data Protection Agency (2008-58-0035), and was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all the participants. The study was registered at ClinicalTrials.gov ID: NCT03022344 and protocol ID: 44110.

Coronary CT angiography

A detailed description of the applied CT acquisition protocol and plaque analysis strategy has been published previously.\textsuperscript{21} In brief, all participants underwent coronary CTA by using a dual-source scanner (SOMATOM Definition Flash; Siemens Healthcare, Forcheim, Germany). Pre-scan oral beta-blockers were administered targeting a heart rate of ≈60 beats/min. Sublingual nitroglycerin, dose of 0.5 mg, was administered 2 to 4 min before the scan. An initial non-contrast enhanced scan for calcium scoring was performed. One experienced CT cardiologist (more than 10 years of experience in coronary CTA interpretation), blinded to all clinical data, analyzed the CT datasets. Vessels >2 mm in diameter were evaluated and graded visually as follows: normal (0%), non-obstructive stenosis (1–29%), intermediate stenosis (30–69%), obstructive stenosis (≥70%). Location of stenosis was reported using a 17-segment model.\textsuperscript{12}

One trained reader performed plaque analysis using a validated semi-automated software program (AutoPlaque, version 2.0, Cedars-Sinai Medical Center, Los Angeles, CA, USA).\textsuperscript{3,25} Total plaque volume and the volumes of calcified plaque (CP), non-calcified plaque (NCP) and low-density NCP (LD-NCP) were assessed. Coronary plaque volumes and characteristics were assessed on a per-patient and a per-vessel basis. All plaque analyses were performed by staff blinded to FFR\textsubscript{CT}-results and other patient data.\textsuperscript{21}

Medical treatment was not affected by the results of coronary CTA or FFR\textsubscript{CT} as these were not available for the treating physicians.

FFR\textsubscript{CT}

Standard acquired coronary CTA data sets were transmitted for central FFR\textsubscript{CT} analysis (HeartFlow Inc., Redwood City, California).\textsuperscript{12} The principles behind FFR\textsubscript{CT} computation have previously been described in detail.\textsuperscript{9} FFR\textsubscript{CT} was displayed for each point in the coronary tree. Any FFR\textsubscript{CT} value in the major coronary arteries ≥1.8 mm in diameter, including side branches, was registered.

The per-patient minimum distal FFR\textsubscript{CT}-value (d-FFR\textsubscript{CT}) was registered. A d-FFR\textsubscript{CT}-value ≤0.75 was indicative of impaired flow.\textsuperscript{26,27}

Follow-up

Electronic patient journals were used to register major adverse outcomes (all-cause mortality, myocardial infarction and stroke) at follow-up, 4 to 6 years after the initial coronary CTA.

Statistical analysis

Continuous variables are presented as mean values and 95% confidence intervals if normally distributed or median and interquartile range (IQR) if non-normally distributed. Categorical variables are presented as frequencies (n) and percentages. Q-plot was used for testing whether the data were normal distributed. Differences in plaques composition between d-FFR\textsubscript{CT} ≤0.75 versus d-FFR\textsubscript{CT} >0.75 were tested using the Wilcoxon rank-sum test. A p-value <0.05 was considered statistically significant. All statistical
analyses were performed using Stata software, version 14.0 (StataCorp LLC, College Station, TX, USA).

**Results**

In total, 115 (54%) patients agreed to participate in this study of whom FFRCT-analysis was available in 76 patients, Figure 1. Clinical characteristics are presented in Table 1. Stenosis severity according to vessel location (n,%) was as follows: normal (n = 150): left anterior descending artery (LAD), 44 (29%); left circumflex artery (CX), 55 (37%); right coronary artery (RCA), 51 (34%); non-obstructive stenosis (n = 69): LAD, 29 (42%); CX, 17 (25%); RCA, 23 (33%); intermediate stenosis (n = 4): LAD, 1 (25%); CX, 2 (50%); RCA, 1 (25%) and obstructive stenosis (n = 5): LAD, 2 (40%); CX, 2 (40%); RCA, 1 (20%). Mean (SD) heart rate was 59 (7) beats/min and median (IQR) radiation dose was 6.0 (4.7–6.9) mSv.

**FFRCT: Plaque relationship**

A total of 43 (57%) patients had plaques. Median (IQR) Agatston score was 1 (0–110) U. Thirty-five (46%) patients had an Agatston score of zero. The d-FFR<sub>CT</sub> median (IQR), was 0.84 (0.79–0.87). d-FFR<sub>CT</sub> was ≤0.75 in 12 (16%) patients. Median (range) d-FFR<sub>CT</sub> in patients with d-FFR<sub>CT</sub> ≤ 0.75 was 0.70 (0.6–0.74). Patients with d-FFR<sub>CT</sub> ≤ 0.75 versus d-FFR<sub>CT</sub> > 0.75 had higher
LDL-cholesterol, while no differences between groups regarding BMI, gender, age, smoking habits, blood pressures or HbA1c were observed, Table 1. Patients with d-FFRCT $\leq 0.75$ versus d-FFRCT $> 0.75$ had numerically higher plaque volumes for all plaque components, however the difference was statistical significance only for the LD-NCP component, Table 2.

**Follow-up**

Follow-up, mean (SD), was performed 4.8 (0.5) years after the index coronary CTA. One patient died due to alcoholic liver cirrhosis (index coronary CTA: Agatston Score, 36 U; non-obstructive CAD; d-FFRCT, 0.91) one had a stroke (index coronary CTA: Agatston Score, 109 U; non-obstructive CAD; d-FFRCT, 0.88) and one patient suffered a myocardial infarction (index coronary CTA: Agatston Score, 1150 U; double-vessel CAD; d-FFRCT, 0.51), Figure 2. For details on stenosis location and severity and coronary plaque volumes, see supplemental material.

**Discussion**

The present study confirms that patients with T2DM have a high burden of CAD already at an early stage of the disease process and demonstrates that every sixth asymptomatic patient with a new diagnosis of T2DM has hemodynamic significant CAD as evaluated by FFR$_{CT}$.

This study provides new knowledge by showing that high-risk coronary features such as coronary flow impairment by FFR$_{CT}$ and adverse plaque characteristics by coronary CTA are frequent in asymptomatic patients with a new diagnosis of T2DM.

Although well-established, coronary CTA is restricted to describe morphological aspects of the atherosclerotic disease process, which has been the basis for evolvement of second-line non-invasive physiological assessment by FFR$_{CT}$-based metrics. The d-FFRCT represents the sum of resistances related to both focal and diffuse atherosclerotic disease along the coronary vessel and thus may be positive even in the absence of focal stenosis and studies in symptomatic populations have demonstrated that adverse plaque characteristics are associated to the presence of coronary pressure loss. The present study adds to these findings by demonstrating similar associations in asymptomatic individuals with newly diagnosed T2DM. Of note, a d-FFRCT $\leq 0.75$ was associated with higher LD-NCP volumes and higher LDL-cholesterol levels. LD-NCP is considered a surrogate for lipid core plaques, and has been associated to unfavorable outcomes. Several imaging and histopathological studies have demonstrated more profound macrophage infiltration and larger necrotic core of coronary plaques in patients with T2DM compared to patients without diabetes. In addition, an abnormal glucose regulation is an important risk factor for coronary plaque progression and is associated with lipid-rich plaques in patients with T2DM compared to non-diabetic subjects. High levels of LDL-cholesterol is a well-known risk factor for cardiovascular events and is associated with the presence of high risk coronary plaques. Otaki et al. showed that a decrease in LDL-cholesterol is associated with plaque stabilization including a decrease in all components of NCP determined by...
coronary CTA. Whether LDL lowering can lead to recovery of abnormal flow is at the moment unresolved. However, the observed association between LDL-cholesterol levels and coronary flow impairment in this study and the long-term improvement of invasive fractional flow reserve following LDL lowering by rosuvastatin in a small series of patients with CAD in a small study Hashikata et al.35 are supportive of this hypothesis.

It is well established that conventional clinical risk factors independently predict the development of CAD in T2DM,36,37 and that multifactorial prevention strategies for late complications are associated with lower rates of micro- and macro-vascular disease.38,39 The present study adds to these findings by demonstrating that a number of asymptomatic patients with T2DM, already at the time of diagnosis, have adverse coronary plaque characteristics with hemodynamic significance.

Information on the occurrence of morphological and physiological adverse plaque characteristics may be of value in identifying high risk patients with asymptomatic T2DM in whom intensive treatment with, for example, proprotein-konvertase-subtilisin/kexin-type 9 inhibitors, glucagon like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors may be considered. These issues need delineation in future studies.

Limitations
The number of participants in the study was small. Both duration of cholesterol-lowering and antihypertensive
medication and changes in cholesterol- and blood pressure levels may have had an impact on coronary flow impairment and plaque phenotype, which could not be accounted for in this study, as these data were not available. Quantitative assessment of plaque volumes is dependent on several conditions. Recent studies indicated that changes in delineation of plaque boundaries and in discriminative Hounsfield levels improved the correlation between plaque volumes determined by intravascular ultrasound and CT angiography.40,41

**Conclusion**

In asymptomatic patients with a new diagnosis of T2DM, coronary flow impairment by FFR_{CT} is frequently seen and is associated to quantitative estimates of coronary plaque components. Studies are needed to assess the value of performing coronary CTA and selective FFR_{CT} for therapeutic management decisions in these patients.

**Author contributions**

MM: designed the study, collected, analyzed and interpreted the data and wrote the report. MM analyzed all CCTA using Autoplaque, did Agatston investigation and FFR analysis; DD: developed the analysis tool and reviewed the manuscript. BN: contributed to the discussion and reviewed the manuscript, JG and JJ: designed the study, and edited the manuscript, MHO: conceived and designed the study and edited the manuscript, NPS: conceived and designed the study, collected, analyzed data and contributed to the discussion and reviewed the manuscript.

**Declaration of conflicting interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The Danish Diabetes Academy supported by the Novo Nordisk Foundation; The Faculty of Health Sciences-University of Southern Denmark; Department of Regional Health Research Center Southwest, Denmark; Edith and Vagn Hedegaard Jensens Foundation, Karola Jorgensens Foundation and Sydvestjysk Cardiologisk Forskningsfund. Bjarne Linde Nørgaard received unrestricted institutional research grants from Siemens and HeartFlow. Damini Dey is a patent-holder of Autoplaque® research software, and receives software royalties from Cedars-Sinai Medical Center, Los Angeles, California, USA. The funders had no role in the study design, data collection, data analysis and interpretation, writing of the report, or the decision to submit the article for publication.

**ORCID iD**

Monija Mrjan
https://orcid.org/0000-0001-9169-5263

**Supplemental material**

Supplemental material for this article is available online.

**References**

1. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. *Eur Heart J* 2020; 41(3): 407–477.
2. Skinner JS, Smeeth L, Kendall JM, et al. NICE guidance. Chest pain of recent onset: assessment and diagnosis of recent onset chest pain or discomfort of suspected cardiac origin. *Heart* 2010; 96(12): 974–978.
3. Dey D, Cheng VY, Slomka PJ, et al. Automated 3-dimensional quantification of noncalcified and calcified coronary plaque from coronary CT angiography. *J Cardiovasc Comput Tomogr* 2009; 3(6): 372–382.
4. Motoyama S, Ito H, Sarai M, et al. Plaque characterization by coronary computed tomography angiography and the likelihood of acute coronary events in mid-term follow-up. *J Am Coll Cardiol* 2015; 66(4): 337–346.
5. Gaur S, Øvrehus KA, Dey D, et al. Coronary plaque quantification and fractional flow reserve by coronary computed tomography angiography identify ischaemia-causing lesions. *Eur Heart J* 2016; 37(15): 1220–1227.
6. Driessen RS, Stuijfzand WJ, Raijmakers PG, et al. Effect of plaque burden and morphology on myocardial blood flow and fractional flow reserve. *J Am Coll Cardiol* 2018; 71(5): 499–509.
7. Ahmadi A, Leipsic J, Øvrehus KA, et al. Lesion-specific and vessel-related determinants of fractional flow reserve beyond coronary artery stenosis. *JACC Cardiovasc Imaging* 2018; 11(4): 521–530.
8. Nakazato R, Shalev A, Doh J-H, et al. Aggregate plaque volume by coronary computed tomography angiography is superior and incremental to luminal narrowing for diagnosis of ischemic lesions of intermediate stenosis severity. *J Am Coll Cardiol* 2013; 62(5): 460–467.
9. Taylor CA, Fonte TA and Min JK. Computational fluid dynamics applied to cardiac computed tomography for non-invasive quantification of fractional flow reserve: scientific basis. *J Am Coll Cardiol* 2013; 61(22): 2233–2241.
10. Driessen RS, Danad I, Stuijfzand WJ, et al. Comparison of coronary computed tomography angiography, fractional flow reserve, and perfusion imaging for ischemia diagnosis. *J Am Coll Cardiol* 2019; 73(2): 161–173.
11. Min JK, Leipsic J, Pencina MJ, et al. Diagnostic accuracy of fractional flow reserve from anatomic CT angiography. *JAMA* 2012; 308(12): 1237–1245.
12. Nørgaard BL, Leipsic J, Gaur S, et al. Diagnostic performance of noninvasive fractional flow reserve derived from coronary computed tomography angiography in suspected coronary artery disease: the NXT trial (analysis of coronary blood flow using CT angiography: next steps). *J Am Coll Cardiol* 2014; 63(12): 1145–1155.
13. Sousa-Uva M, Neumann F-J, Ahlsson A, et al. 2018 ESC/EACTS guidelines on myocardial revascularization. *Eur J Cardiothorac Surg* 2019; 55(1): 4–90.
14. Sand NPR, Veien KT, Nielsen SS, et al. Prospective comparison of FFR derived from coronary CT angiography with SPECT perfusion imaging in stable coronary artery disease:
the ReASSESS study. *JACC Cardiovasc Imaging* 2018; 11(11): 1640–1650.

15. Sand NPR, Nissen L, Wintner S, et al. Prediction of coronary revascularization in stable angina: comparison of FFR<sub>CT</sub> with CMR stress perfusion imaging. *JACC Cardiovasc Imaging* 2020; 13(4): 994–1004.

16. Jensen JM, Botker HE, Mathiassen ON, et al. Computed tomography derived fractional flow reserve testing in stable patients with typical angina pectoris: influence on downstream rate of invasive coronary angiography. *Eur Heart J Cardiovasc Imaging* 2018; 19(4): 405–414.

17. Fairbairn TA, Nieman K, Akasaka T, et al. Real-world clinical utility and impact on clinical decision-making of coronary computed tomography angiography-derived fractional flow reserve: lessons from the ADVANCE registry. *Eur Heart J* 2018; 39(41): 3701–3711.

18. Patel MR, Nørgaard BL, Fairbairn TA, et al. 1-Year impact on medical practice and clinical outcomes of FFR<sub>CT</sub>: the ADVANCE registry. *JACC Cardiovasc Imaging* 2020; 13: 97–105.

19. Ihdayhid AR, Nørgaard BL, Gaur S, et al. Prognostic value and risk of noninvasive fractional flow reserve derived from coronary CT angiography. *Radiology* 2019; 292(2): 343–351.

20. Nørgaard BL, Terkelsem CJ, Mathiassen ON, et al. Coronary CT angiographic and flow reserve-guided management of patients with stable ischemic heart disease. *J Am Coll Cardiol* 2018; 72(18): 2123–2134.

21. Mrgan et al. Prognostic value and risk of noninvasive fractional flow reserve derived from coronary CT angiography. *Diabetes Vasc Dis Res* 2017; 14(6): 468–476.

22. Nakanishi R, Ceponiene I, Osawa K, et al. Plaque progression assessed by a novel semi-automated quantitative plaque software on coronary computed tomography angiography between diabetes and non-diabetes patients: a propensity-score matching study. *Atherosclerosis* 2016; 255: 73–79.

23. Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I. *Circulation* 2003; 108(14): 1664–1672.

24. Muhlestein JB, Lappé DL, Lima JAC, et al. Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomized clinical trial. *JAMA* 2014; 312(21): 2234–2243.

25. Dey D, Schepis T, Marwan M, et al. Automated three-dimensional quantification of noncalcified coronary plaque from coronary CT angiography: comparison with intravascular US. *Radiology* 2010; 257(2): 516–522.

26. Doris MK, Otaki Y, Armson Y, et al. Non-invasive fractional flow reserve in vessels without severe obstructive stenosis is associated with coronary plaque burden. *J Cardiovasc Comput Tomogr* 2018; 12(5): 379–384.

27. Nørgaard BL, Fairbairn TA, Safian RD, et al. Coronary CT angiography-derived fractional flow reserve testing in patients with stable coronary artery disease: recommendations on interpretation and reporting. *Radiol Cardiothorac Imaging* 2019; 1(5): e190050.

28. Ahmadi A, Kini A and Narula J. Discordance between ischemia and stenosis, or PINSS and NIPSS: are we ready for new vocabulary? *JACC Cardiovasc Imaging* 2015; 8(1): 111–114.

29. Amano T, Matsubara T, Uetani T, et al. Abnormal glucose regulation is associated with lipid-rich coronary plaque: relationship to insulin resistance. *JACC Cardiovasc Imaging* 2008; 1(1): 39–45.

30. Burke AP, Kolodgie FD, Zieske A, et al. Morphologic findings of coronary atherosclerotic plaques in diabetics: a post-mortem study. *Arterioscler Thromb Vasc Biol* 2004; 24(7): 1266–1271.

31. Virmani R, Burke AP and Kolodgie F. Morphological characteristics of coronary atherosclerosis in diabetes mellitus. *Can J Cardiol* 2006; 22(Suppl. B): 81B–84B.

32. Nasu K, Tsuchikane, Katoh O, et al. Plaque characterisation by virtual histology intravascular ultrasound analysis in patients with type 2 diabetes. *Heart* 2008; 94(4): 429–433.

33. Kojima S, Kojima S, Maruyoshi H, et al. Hypercholesterolemia and hypoadiponectinemia are associated with necrotic core-rich coronary plaque. *Int J Cardiol* 2011; 147(3): 371–376.

34. Otaki Y, Tamarappoo B, Cadet SJ, et al. Decrease in LDL-C is associated with decrease in all components of noncalcified plaque on coronary CTA. *Atherosclerosis* 2019; 285: 128–134.

35. Hashikata T, Tojo T, Muramatsu Y, et al. Lower level of low density lipoprotein cholesterol is associated with a higher increase in the fractional flow reserve in patients with fixed-dose Rosuvastatin. *J Atheroscler Thromb* 2018; 25(3): 233–243.

36. Sarwar N, Gao P, Seshasai SRK, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. *Lancet* 2010; 375(9733): 2215–2222.

37. D’Agostino RB Sr, Grundy S, Sullivan LM, et al. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. *JAMA* 2001; 286(2): 180–187.

38. Gaede P, Parving HH, Pedersen O, et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. *Lancet* 1999; 353(9153): 617–622.

39. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. *N Engl J Med* 2003; 348(5): 383–393.

40. Matsumoto H, Watanabe S, Kyo E, et al. Improved evaluation of lipid-rich plaque at coronary CT angiography: head-to-head comparison with intravascular US. *Radiol Cardiothorac Imaging* 2019; 1(5): e190069.

41. Matsumoto H, Watanabe S, Kyo E, et al. Standardized volumetric plaque quantification and characterization from coronary CT angiography: a head-to-head comparison with invasive intravascular ultrasound. *Eur Radiol* 2019; 29(11): 6129–6139.